Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects.

Die Pharmazie - 1 May 2017

Mladenovska K, Grapci A Daka, Vavlukis M, Kapedanovska A, Eftimov A, Geshkovska N Matevska, Nebija D, Dimovski A J

Abstract excerpt

Atorvastatin, as 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, is a widely prescribed medication for the treatment of dyslipidemia. However, despite its clinical efficacy in reducing major cardiovascular events, a wide inter-individual variability in its response exists. Several studies in this area point to the effect of polymorphisms in the solute carrier organic anion transporter 1B1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Aged
Share to Atorvastatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hyperlipoproteinemia Type II

Share to Lipids

Share to Liver-Specific Organic Anion Transporter 1

Source

Identifiers

PMID: 29441875
DOI: 10.1801/ph.2017.6960

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects.PMID 29441875Read ↗

Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.Semantic proximity Read ↗

No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.Semantic proximity Read ↗

The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.Semantic proximity Read ↗

Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.Semantic proximity Read ↗

Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.Semantic proximity Read ↗

Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort.Semantic proximity Read ↗

Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.Semantic proximity Read ↗

SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians.Semantic proximity Read ↗

Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).Semantic proximity Read ↗

Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.Semantic proximity Read ↗

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin BioavailabilitySemantic proximity Read ↗

Impact of SLCO1B1 and ABCB1 variants on statin efficacy and toxicity in a Tunisian population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.